Pay in 4 interest-free payments of $13.75 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
CAS Number: 778270-11-4
EHT 1864 specifically inhibits glucose-induced Rac1 activation and membrane association and associated downstream signaling events culminating in inhibition of GSIS
21(5):323-331
is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway
an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drugs usage to severe refractory epilepsy
CC-930 - CAS# 899805-25-5 Catalog No.:M6544-10 CAS Number: 778270-11-4CC 930, also known as Tanzisertib, CAS No. 899805 25 5, is a potent, selective, and orally active JNK inhibitor with potential antifibrotic activity. CC 930 entered Phase I clinical trials. Tanzisertib may have potential use for prevention and treatment of dermal fibrosis. Selective inhibition of JNK by CC 930 exerted potent antifibrotic effects in vitro and in different models in vivo. JNK might thus be a novel molecular target for the treatment of
US$ 61.00
US$ 39.95
US$ 18.95
US$ 22.45
US$ 1530.00